Empreses emergents
2006
CHEMOTARGETS SLChemotargets desenvolupa solucions innovadores de ciència de dades per aprofitar plenament els coneixements de les dades experimentals i els resultats predits Chemotargets CLARITY®, la plataforma de visualització i anàlisi de dades més avançada per a farmacologia predictiva i seguretat
Adreça
Carrer de Baldiri Reixac 15, 08028 Barcelona, Espanya
Propietat CERCA
Barcelona, Spain
1992
Hospital del Mar Research Institute (HMRIB)
Contacte del Centre CERCA
IÁ
Ismael Ávila
Hospital del Mar Research Institute (HMRIB)Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
Chemotargets offers validated and cutting-edge computational methodologies with top market predictive performance. The innovation strategy of the company is driven by new methods generated at Dr. Mestres’ lab.
Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and improving cost-efficiency and safety.
Chemotargets is currently recognized as a global leader in predictive analytics solutions for pharmaceutical and biotechnology companies and research institutions.
Since May 2017, Prous Institute for Biomedical Research does strategic investment in Chemotargets SL which allows CLARITYⓇ product development to be accelerated
Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and improving cost-efficiency and safety.
Chemotargets is currently recognized as a global leader in predictive analytics solutions for pharmaceutical and biotechnology companies and research institutions.
Since May 2017, Prous Institute for Biomedical Research does strategic investment in Chemotargets SL which allows CLARITYⓇ product development to be accelerated
Descripció del producte
Chemotargets CLARITY® is an innovative data science solution that fully exploits the synergies between known experimental results and predicted insights to discover hidden knowledge, untap new competitive opportunities and improve R&D efficiencies.
CLARITYⓇ enables global profiling for a given molecule or set:
Quantitative binding and functional activity for mechanisms of action associated with therapeutic activities and safety liabilities (PHARMACOLOGY and SAFETY).
Predicted metabolites and their pharmacological profiles, and comparison with substrates (METABOLISM).
CLARITYⓇ ‘s engine uses:
An expertly curated training set of 2.6 million compounds data derived from patents, journals and public databases to ensure comprehensive coverage of the chemical space pharmacology, and covers related drug safety information available.
Multiple integrated state-of-the-art computational methods to ensure high level of confidence.
- Predicted target affinities with 6 independent approaches
- Predicted safety associations with 4 independent approaches
- Consensus confidence scores provided for each predicted interaction
- Prediction of metabolites, using a manually curated training dataset of experimental biotransformations in xenobiotics, including both Phase I and II metabolic reactions, extracted from the literature
- Comparative pharmacology between substrate and metabolites
- Coverage of a broad range of target-actions essential for secondary pharmacology profiling and provides information on the adverse effects linked to these mechanisms of action
- Improved analytics and visualisation tools that allow direct access to known data, both internal (if integrated) and external, and fast generation of predicted data
- Advanced Interpretation tools
CLARITYⓇ enables global profiling for a given molecule or set:
Quantitative binding and functional activity for mechanisms of action associated with therapeutic activities and safety liabilities (PHARMACOLOGY and SAFETY).
Predicted metabolites and their pharmacological profiles, and comparison with substrates (METABOLISM).
CLARITYⓇ ‘s engine uses:
An expertly curated training set of 2.6 million compounds data derived from patents, journals and public databases to ensure comprehensive coverage of the chemical space pharmacology, and covers related drug safety information available.
Multiple integrated state-of-the-art computational methods to ensure high level of confidence.
- Predicted target affinities with 6 independent approaches
- Predicted safety associations with 4 independent approaches
- Consensus confidence scores provided for each predicted interaction
- Prediction of metabolites, using a manually curated training dataset of experimental biotransformations in xenobiotics, including both Phase I and II metabolic reactions, extracted from the literature
- Comparative pharmacology between substrate and metabolites
- Coverage of a broad range of target-actions essential for secondary pharmacology profiling and provides information on the adverse effects linked to these mechanisms of action
- Improved analytics and visualisation tools that allow direct access to known data, both internal (if integrated) and external, and fast generation of predicted data
- Advanced Interpretation tools